The new medications are currently not covered by Taiwan’s health insurance system but are available to patients who can pay ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Jim Rogers, 58, was living and working in Australia when he started to develop symptoms of the incurable neurological ...

And other biotech news brought to you by The Readout.

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.